A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer
Authors:
- 23 February 2013
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 71 (5) , 1173-1182
Abstract
Background Preclinical studies demonstrated antiproliferative synergy of 1,25-D3 (calcitriol) with cisplatin. The goals of this phase I/II study were to determine the recommended phase II dose (RP2D) of 1,25-D3 with cisplatin and docetaxel and its efficacy in metastatic non-small-cell lung cancer. Methods Patients were ≥18 years, PS 0–1 with normal organ function. In the phase I portion, patients received escalating doses of 1,25-D3 intravenously every 21 days prior to docetaxel 75 mg/m2 and cisplatin 75 mg/m2 using standard 3 + 3 design, targeting dose-limiting toxicity (DLT) rate T) correlated with disease progression (P = 0.03) and CYP24A1 SNP rs2762939 (C > G) trended toward PR/SD (P = 0.08). There was no association between 1,25-D3 PK and CYP24A1 SNPs. Conclusions The RP2D of 1,25-D3 with docetaxel and cisplatin was 60 mcg/m2 every 21 days. Pre-specified endpoint of 50 % confirmed RR was not met in the phase II study. Functional SNPs in CYP24A1 may inform future studies individualizing 1,25-D3.Keywords
This publication has 26 references indexed in Scilit:
- CYP24A1Is an Independent Prognostic Marker of Survival in Patients with Lung AdenocarcinomaClinical Cancer Research, 2011
- Association of the Vitamin D Metabolism Gene CYP24A1 With Coronary Artery CalcificationArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (Calcitriol) in combination with dexamethasone for castration‐resistant prostate cancerCancer, 2010
- A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2009
- A novel SNP in a vitamin D response element of the CYP24A1 promoter reduces protein binding, transactivation, and gene expressionThe Journal of Steroid Biochemistry and Molecular Biology, 2008
- In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumorsCancer Chemotherapy and Pharmacology, 2008
- Vitamin D signalling pathways in cancer: potential for anticancer therapeuticsNature Reviews Cancer, 2007
- A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid TumorsClinical Cancer Research, 2007
- Phase III Randomized Trial of Docetaxel Plus Cisplatin Versus Vindesine Plus Cisplatin in Patients With Stage IV Non-Small-Cell Lung Cancer: The Japanese Taxotere Lung Cancer Study GroupJournal of Clinical Oncology, 2004
- Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study GroupJournal of Clinical Oncology, 2003